Olaparib for Metastatic Castration-Resistant Prostate Cancer

Abstract

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.).

Keywords

OlaparibPoly ADP ribose polymeraseProstate cancerHomologous recombinationPARP inhibitorDNA repairCancer researchPolymeraseDNA Damage RepairMedicineProstateGeneOncologyCancerBiologyInternal medicineGenetics

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Author response: DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis

Ben Taylor , Serena Nik‐Zainal , Yee Ling Wu +6 more

Article Figures and data Abstract eLife digest Introduction Results Discussion Materials and methods References Decision letter Author response Article and author information Me...

2013 4 citations

Publication Info

Year: 2020
Type: article
Volume: 382
Issue: 22
Pages: 2091-2102
Citations: 2067
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Olaparib for Metastatic Castration-Resistant Prostate Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2067

OpenAlex

Cite This

APA Style

                            
                                
                                    Johann S. de Bono, 
                                
                                    Joaquı́n Mateo, 
                                
                                    Karim Fizazi
                                
                                et al.
                            
                            (2020). 
                            Olaparib for Metastatic Castration-Resistant Prostate Cancer. 
                            New England Journal of Medicine
                            , 382
                            (22)
                            , 2091-2102.
                            https://doi.org/10.1056/nejmoa1911440
                        

Identifiers

DOI: 10.1056/nejmoa1911440